The effectiveness of clonazepam on the Rolandic discharges. 1997

A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
Department of Pediatrics, Fukuoka University, School of Medicine, Japan.

Rolandic discharge (RD), noted in the electroencephalography (EEG) of patients with benign epilepsy in childhood with centrotemporal spikes (BECCT) has several unique features. One feature is that the amount or frequency of RDs does not correlate well with the incidence of seizures in BECCT although it is a key finding in the diagnosis of this epileptic syndrome. In this study, we examined the efficacy of antiepileptic drugs focusing on the disappearance of RDs in relationship with seizure control. Forty patients with BECCT who were not medically treated prior to this study were randomly sorted into three groups. Twenty patients were assigned for clonazepam (CZP) treatment, 10 patients for valproate (VPA) and the remaining 10 patients for carbamazepine (CBZ). Each drug was administered for 4 consecutive weeks. EEGs were recorded twice during the study, before and 4 weeks after the medication trial. The effects of each treatment on RDs were assessed. RDs disappeared in 15 of the 20 cases treated with CZP (75%) within 4 weeks while the same was observed in only one of the 10 cases treated with VPA (10%). CBZ failed to demonstrate any effect on RD. In the group treated with CZP, there were no differences in seizure incidence, seizure type and blood concentration of CZP between the patients whose RDs disappeared and those whose RDs remained.

UI MeSH Term Description Entries
D008297 Male Males
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002998 Clonazepam An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-,Klonopin,Antelepsin,Rivotril,Ro 5-4023,Ro 54023
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
October 2010, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 1981, Brain & development,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 1980, Folia psychiatrica et neurologica japonica,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 1996, Electroencephalography and clinical neurophysiology. Supplement,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 1980, Folia psychiatrica et neurologica japonica,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 2001, Revista de neurologia,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
February 2003, Epilepsia,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
January 2002, Revista de neurologia,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
December 1973, Epilepsia,
A Mitsudome, and M Ohfu, and S Yasumoto, and A Ogawa, and S Hirose, and H Ogata, and T Yamada
June 2004, Journal of child neurology,
Copied contents to your clipboard!